ORLANDO, Fla. — The Florida Department of Health held its first public workshop Friday on the subject of changing state rules regarding vaccines. It’s part of an ongoing push led by the state’s ...
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
FDA approves 1st chronic HDV treatment Hepcludex to reduce virus levels and improve liver function in adults with hepatitis delta virus.
European regulators have recommended expanding Maviret, a dual direct-acting antiviral, to include acute hepatitis C infection in adults and children.
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA due to manufacturing and delivery concerns, the treatment has since redeemed itself by scoring a green ...
Asianet Newsable on MSN
Hepatitis B & C: Preventable liver diseases still killing millions worldwide
From a clinical perspective, these are conditions in which outcomes can change significantly. But that depends on when we ...
In conjunction with World Hepatitis Day, observed annually on July 28, the Ministry of Health announced significant progress ...
US FDA grants accelerated approval to Gilead’s Hepcludex for the treatment of chronic hepatitis delta virus: Foster City, California Tuesday, May 26, 2026, 10:00 Hrs [IST] Gilea ...
Chronic hepatitis delta virus (HDV) infection has its first FDA-approved treatment, after the agency granted accelerated approval to bulevirtide (Hepcludex) injection for adults without cirrhosis or ...
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex® (bulevirtide-gmod) 8.5 mg for the treatment of adults living with ...
AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of its treatment for acute hepatitis C. The final ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results